Celltrion Begins Global Phase 3 Clinical Trial for Its Bevacizumab Biosimilar 'CT-P16'

World News: 06:06 GMT Friday 10th August 2018. [Celltrion, Inc. via Businesswire via SPi World News]

• SPi News Home
• Latest News
• News for 2018-08-10
• Celltrion Begins Global Phase 3 Clinical Trial for Its Bevacizumab Biosimilar 'CT-P16'

Celltrion Inc KRX068270 is set to launch global Phase 3 clinical trial for its bevacizumab biosimilar ‘CT-P16’ for the treatment of cancer Celltrion successfully completed Phase 1 clinical study on the sa fety ...

More news and information about Celltrion, Inc.

Published By:

Business Wire: 06:06 GMT Friday 10th August 2018

Published: 2018-08-10T06:06:00.

Search for other references to "celltrion" on SPi News